The clinical course following intravenous metallic mercury is unknown and ideal management has not been defined. The effects of a bolus dose seem to vary from the inconsequential to the rapidly fatal. CASEREPORT. A previously healthy twenty-six year old woman presented to casualty about one hour after self -injection with metallic mercury using her boyfriend's insulin syringe. The mercury had been taken from an old thermometer in an attempt at suicide following an argument. She smoked 20 cigarettes a day; there was no previous medical history. On examination there was some localised inflammation in the right ante-cubital fossa and mercury was palpable subcutaneously. There were no other abnormal physical findings. Radiological examination of the chest and the ante-cubital fossa confirmed the presence of mercury in the forearm veins and in the pulmonary vasculature ( Figs. I and 2) . Fig2. Multiple metallic densities are seen in the distribution of the pulmonary vascular bed.
She was commenced on intramuscular dimercaprol for 1 1 days followed by a two year course of its oral analogue dimercaptopropane-I -sulfonate (DMPS). During the second week she was treated with oral penicillamine. Ten days after admission much of the mercury remaining in her forearm was surgically removed. Two years after treatment with DMPS had been commenced, it was discontinued at her request as she found it inconvenient and was not convinced it was of any continuing benefit. Throughout the three year follow-up she remained asymptomatic. Blood gases on admission showed a partial pressure of oxygen(PaO2) of 104 mmHg, which deteriorated after four days to 85 mmHg but subsequently returned to normal. Pulmonary function tests were performed after 17 days: forced expiratory volume in one second was 122% predicted, forced vital capacity 122% predicted residual volume 51% predicted and total lung capacity 96% predicted. Transfer factor was 72% predicted by the single breath technique and when corrected for lung volume 94% predicted. These improved after one month when transfer factor was 81% predicted and 100% predicted when corrected for lung volume. Forty months after presentation transfer factor was 85% predicted and when corrected for lung volume 95% predicted. Chest x-ray remained unchanged throughout the clinical course. Full blood picture, liver, renal and thyroid function tests have remained within normal limits. Serum and urinary mercury levels have been monitored over the three year follow-up. Blood mercury levels which were initially 1000 nmol/I fell to 300-400 nmol/l [normal less than 25 nmol/l] after administration of DMPS and have remained at that level following the discontinuation of this treatment.
i The Ulster Medical Society, 1993.
The Ulster Medical Journal Urinary collections for mercury have been less consistent but rose from 300 nmol/ day to nearly 13,000 nmol/day when DMPS was commenced. Urinary excretion fell to around 3,000 nmol/day within a few weeks and has remained fairly constant in spite of stopping the DMPS. Normal urinary mercury excretion is less than 100 nmol/day (Fig. 3) . DISCUSSION Giobetti et al.' reviewed 24 previously published reports of intravenous injection of metallic mercury which included ten cardiac catheterisation accidents. At least 12 of the patients who were followed up remained asymptomatic throughout. Two cardiac catheter accidents were complicated by neurological signs and symptoms which were consistent with systemic emboli. Two further patients developed sepsis and one died. Seven patients reported pleuritic chest pain but only four complained of dyspnoea. Abnormal pulmonary function tests and blood gases were much more common than symptoms but most seemed to resolve. Five patients had evidence of renal disease, varying from proteinuria to a decline in the creatinine clearance and elevation of urea. Treatment of these patients for mercury toxicity was not documented. 
